These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 19092365

  • 1. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G, Klapholz M.
    Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
    [Abstract] [Full Text] [Related]

  • 2. Vasopressin: a new target for the treatment of heart failure.
    Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheorghiade M, Adams KF.
    Am Heart J; 2003 Jul; 146(1):9-18. PubMed ID: 12851603
    [Abstract] [Full Text] [Related]

  • 3. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.
    Rosner MH, Ronco C.
    Congest Heart Fail; 2010 Jul; 16 Suppl 1():S7-14. PubMed ID: 20653716
    [Abstract] [Full Text] [Related]

  • 4. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
    Schwarz ER, Sanghi P.
    Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
    [Abstract] [Full Text] [Related]

  • 5. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
    Goldsmith SR.
    Am J Cardiol; 2005 May 02; 95(9A):14B-23B. PubMed ID: 15847853
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 May 02; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 7. Vasopressin antagonism: a future treatment option in heart failure.
    Sanghi P, Uretsky BF, Schwarz ER.
    Eur Heart J; 2005 Mar 02; 26(6):538-43. PubMed ID: 15695526
    [Abstract] [Full Text] [Related]

  • 8. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT, Palaniyandi SS, Yamaguchi K, Komai Y, Thandavarayan RA, Sukumaran V, Watanabe K.
    Drug Discov Today; 2010 Oct 02; 15(19-20):826-41. PubMed ID: 20708094
    [Abstract] [Full Text] [Related]

  • 9. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization.
    De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M.
    Am J Cardiol; 2005 Dec 19; 96(12A):24L-33L. PubMed ID: 16399090
    [Abstract] [Full Text] [Related]

  • 10. Vasopressin excess and hyponatremia.
    Pham PC, Pham PM, Pham PT.
    Am J Kidney Dis; 2006 May 19; 47(5):727-37. PubMed ID: 16632011
    [Abstract] [Full Text] [Related]

  • 11. The potential role for lixivaptan in heart failure and in hyponatremia.
    Zmily HD, Khan NS, Daifallah S, Ghali JK.
    Expert Opin Investig Drugs; 2011 Jun 19; 20(6):831-48. PubMed ID: 21548825
    [Abstract] [Full Text] [Related]

  • 12. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A, Menon MC.
    Curr Opin Investig Drugs; 2010 Sep 19; 11(9):1007-14. PubMed ID: 20730695
    [Abstract] [Full Text] [Related]

  • 13. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2008 Mar 15; 75(6):1322-30. PubMed ID: 18179782
    [Abstract] [Full Text] [Related]

  • 14. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH, Serrano C.
    Int J Cardiol; 2007 Aug 09; 120(1):1-9. PubMed ID: 17346825
    [Abstract] [Full Text] [Related]

  • 15. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P.
    Arch Mal Coeur Vaiss; 2006 Mar 09; 99(3):215-20. PubMed ID: 16618024
    [Abstract] [Full Text] [Related]

  • 16. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2007 Nov 15; 74(10):1466-75. PubMed ID: 17720144
    [Abstract] [Full Text] [Related]

  • 17. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B, Shiekh H, Karram T, Rubinstein I, Azzam ZS, Abu-Saleh N, Nitecki S, Winaver J, Hoffman A, Abassi ZA.
    J Pharmacol Exp Ther; 2008 Aug 15; 326(2):414-22. PubMed ID: 18467593
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of vasopressin receptor antagonists.
    Ali F, Guglin M, Vaitkevicius P, Ghali JK.
    Drugs; 2007 Aug 15; 67(6):847-58. PubMed ID: 17428103
    [Abstract] [Full Text] [Related]

  • 19. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.
    Rai A, Whaley-Connell A, McFarlane S, Sowers JR.
    Am J Nephrol; 2006 Aug 15; 26(6):579-89. PubMed ID: 17170524
    [Abstract] [Full Text] [Related]

  • 20. Neurohormonal activation in congestive heart failure and the role of vasopressin.
    Chatterjee K.
    Am J Cardiol; 2005 May 02; 95(9A):8B-13B. PubMed ID: 15847852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.